Glycosylated Recombinant Human Interleukin-7

BIOLOGICAL3 trials

Conditions

Advanced Bladder Urothelial CarcinomaAdvanced Ureter Urothelial CarcinomaBladder CancerBreast CancerCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaColon CancerMetastatic Bladder Urothelial Carcinoma

Phase 2

Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

TerminatedNCT01339000

National Cancer Institute (NCI)Bladder Cancer, Breast Cancer, Colon Cancer

Start: 2011-04-30End: 2016-04-30Updated: 2016-06-22

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

CompletedNCT01881867

Fred Hutchinson Cancer CenterCastration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma +1

Start: 2013-09-10End: 2018-01-02Updated: 2019-07-09

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

CompletedNCT03513952

National Cancer Institute (NCI)Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma +21

Start: 2019-06-05End: 2024-04-01Updated: 2024-07-26

Journal of Clinical Oncology2024-01-29

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer2021-08-0162 citations

263 Pleiotropic effects of IL-7 in prostate cancer patients receiving Sipuleucel-T vaccination

Regular and Young Investigator Award Abstracts2020-11-01

A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14).

Journal of Clinical Oncology2019-05-202 citations

Glycosylated Recombinant Human Interleukin-7

Sponsors

Conditions

Phase 2

Related Papers